The historical rank and industry rank for Veracyte's Net Cash per Share or its related term are showing as below:
VCYT'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.65 Med: 13.82 Max: 848
Current: 11.04
During the past 13 years, the highest Price-to-Net-Cash Ratio of Veracyte was 848.00. The lowest was 5.65. And the median was 13.82.
VCYT's Price-to-Net-Cash is ranked worse than 77.61% of 67
companies
in the Medical Diagnostics & Research industry
Industry Median: 6
vs VCYT: 11.04
Veracyte Net Cash per Share Historical Data
The historical data trend for Veracyte's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Veracyte's Net Cash per Share
For the Diagnostics & Research subindustry, Veracyte's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Veracyte's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Veracyte's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (NAS:VCYT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Veracyte Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Veracyte's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCYT has been successfully added to your 